Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …

The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab
plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory …

PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months,
daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly …

Background Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces
direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy …

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly
reduced risk of progression/death versus lenalidomide/dexamethasone alone in …

Introduction: Daratumumab, a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action, is approved in combination …

Introduction: Daratumumab (DARA) is approved across lines of therapy for multiple
myeloma. In the primary analysis of the randomized phase 2 GRIFFIN trial (NCT02874742) …

Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38
with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved as …

Background Standard-of-care treatment for patients with newly diagnosed multiple myeloma
includes combination therapies for patients who are not eligible for autologous stem-cell …

Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …